A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)

Trial Profile

A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Pazopanib (Primary) ; Temozolomide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Mar 2016 Protocol amended as treatment arms changed from 1 to 5 as reported by ClinicalTrials.gov.
    • 15 Mar 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 24 Aug 2015 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top